2021
Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States
Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation Cardiovascular Quality And Outcomes 2021, 14: e008381. PMID: 34779654, PMCID: PMC9022137, DOI: 10.1161/circoutcomes.121.008381.Peer-Reviewed Original ResearchConceptsType 2 diabetesMedicare beneficiariesSodium-glucose cotransporter 2 inhibitorsLarge randomized clinical trialsMedicare Part D prescriber dataChronic kidney diseaseCotransporter 2 inhibitorsAtherosclerotic cardiovascular diseasePercent of cliniciansRandomized clinical trialsUS Medicare beneficiariesAdvanced practice providersCross-sectional studyKidney outcomesSGLT2i useSulfonylurea prescriptionUnique cliniciansCardiovascular deathMedication classesKidney diseaseLabel indicationsClinical trialsSGLT2iCardiovascular diseasePractice providers
2018
Sex differences in health outcomes at one year following acute myocardial infarction: A report from the China Patient-Centered Evaluative Assessment of Cardiac Events prospective acute myocardial infarction study
Dreyer RP, Zheng X, Xu X, Liu S, Li J, Ding Q, Du X, Li X, Zhang H, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. Sex differences in health outcomes at one year following acute myocardial infarction: A report from the China Patient-Centered Evaluative Assessment of Cardiac Events prospective acute myocardial infarction study. European Heart Journal Acute Cardiovascular Care 2018, 8: 273-282. PMID: 30270637, DOI: 10.1177/2048872618803726.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDisease-specific health statusAdverse cardiac eventsAcute myocardial infarctionGeneric health statusMyocardial infarctionCardiac eventsFemale sexHealth statusWeekly anginaChina PatientHealth outcomesAcute Myocardial Infarction StudyPost-acute myocardial infarctionAcute myocardial infarction patientsLong-term health outcomesCardiac Events (PEACE) studyMyocardial Infarction StudyMyocardial infarction patientsSpecific health statusHigher crude ratesSex differencesCardiovascular deathMultivariable analysisInfarction patients
2007
Identifying Heart Failure Patients at High Risk for Near-Term Cardiovascular Events With Serial Health Status Assessments
Kosiborod M, Soto GE, Jones PG, Krumholz HM, Weintraub WS, Deedwania P, Spertus JA. Identifying Heart Failure Patients at High Risk for Near-Term Cardiovascular Events With Serial Health Status Assessments. Circulation 2007, 115: 1975-1981. PMID: 17420346, DOI: 10.1161/circulationaha.106.670901.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireHeart failure outpatientsHealth status assessmentCause mortalityCardiovascular mortalityKaplan-Meier survival analysisHigh-risk patientsHeart failure patientsAcute myocardial infarctionProportional hazards modelIntensity of treatmentStatus assessmentKCCQ scoresCardiovascular deathCardiovascular eventsClinical deteriorationMultivariable adjustmentFailure patientsHeart failureOutpatient visitsMyocardial infarctionHigh riskHospitalizationPatientsCombined outcome
2006
Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors